SEC Comment Letter for CBD Life Sciences Inc. (CBDL) (CIK 0001776073) (CBDL) — Feb 27, 2020
CBD Life Sciences Inc. (CBDL) (CIK 0001776073)
Date: Feb. 27, 2020 · CIK: 0001776073 · Accession: 0000000000-20-001787
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-11005
Letter
February 27, 2020 Lisa Nelson Chief Executive Officer CBD Life Sciences Inc. 11445 E. Via Linda, Unit 2-496 Scottsdale, AZ 85259 Re:CBD Life Sciences Inc. Amendment No. 8 to Offering Statement on Form 1-A Filed February 25, 2020 File No. 024-11005 Dear Ms. Nelson: We have reviewed your amended offering statement and have the following comment. Please respond to this letter by amending your offering statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your offering statement and the information you provide in response to this comment, we may have additional comments. Amendment No. 8 to Offering Statement on Form 1-A General 1.We note that the legal opinion is limited to New York law. Please have counsel revise the legal opinion to opine as to the laws of Nevada, your state of incorporation.
FirstName LastNameLisa Nelson Comapany NameCBD Life Sciences Inc. February 27, 2020 Page 2 FirstName LastName Lisa Nelson CBD Life Sciences Inc. February 27, 2020 Page 2 You may contact Rolf Sundwall at 202-551-3105 or Lisa Vanjoske at 202-551-3614 if you have questions regarding comments on the financial statements and related matters. Please contact Ada D. Sarmento at 202-551-3798 or Joe McCann at 202-551-6262 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John E. Lux, Esq.
Show Raw Text
February 27, 2020
Lisa Nelson
Chief Executive Officer
CBD Life Sciences Inc.
11445 E. Via Linda, Unit 2-496
Scottsdale, AZ 85259
Re:CBD Life Sciences Inc.
Amendment No. 8 to Offering Statement on Form 1-A
Filed February 25, 2020
File No. 024-11005
Dear Ms. Nelson:
We have reviewed your amended offering statement and have the following comment.
Please respond to this letter by amending your offering statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your offering statement and the information you
provide in response to this comment, we may have additional comments.
Amendment No. 8 to Offering Statement on Form 1-A
General
1.We note that the legal opinion is limited to New York law. Please have counsel revise the
legal opinion to opine as to the laws of Nevada, your state of incorporation.
FirstName LastNameLisa Nelson
Comapany NameCBD Life Sciences Inc.
February 27, 2020 Page 2
FirstName LastName
Lisa Nelson
CBD Life Sciences Inc.
February 27, 2020
Page 2
You may contact Rolf Sundwall at 202-551-3105 or Lisa Vanjoske at 202-551-3614 if
you have questions regarding comments on the financial statements and related matters. Please
contact Ada D. Sarmento at 202-551-3798 or Joe McCann at 202-551-6262 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: John E. Lux, Esq.